...the panel recommends pembrolizumab or nivolumab, alone or in combination with ipilimumab, as first-line treatment options for patients with MSI-H/dMMR mCRC, whether or not they are eligible for intensive therapy.

dMMR and MSI-H were confirmed after one cycle of capecitabine oral administration for a distal T3N1M0 rectal cancer patient, demonstrating that immunotherapy alone was applied in her case. Pembrolizumab was given for six cycles with the addition of Ipilimumab in the second and third cycles. Clinical complete response (cCR) of the tumor was found after the sixth cycle of immunotherapy.